Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma

Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma

Abstract Background Dysregulated amino acid metabolism creates cancer-specific vulnerabilities. Neuroblastoma tumors have dysregulated arginine metabolism that renders them sensitive to systemic arginine deprivation. Arginase therapy has been proposed as a therapeutic approach for neuroblastoma trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Kimberley M. Hanssen, Jayne Murray, Ruby Pandher, Stephanie Alfred, Laura D. Gamble, Jennifer Brand, Erin Mosmann, Frances K. Kusuma, Crystal Mak, Adam Kearns, Alvin Kamili, Caroline Atkinson, Alexis Z. Minchaca, Jean Bertoldo, David S. Ziegler, Francis Mussai, Paul N. M. Cheng, Murray D. Norris, Jamie I. Fletcher, Michelle Haber
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Neuroblastoma
Arginine
Arginase
Metabolism
Preclinical testing
Patient-derived xenografts
Online Access:https://doi.org/10.1186/s13046-025-03502-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-025-03502-8

Similar Items